156 related articles for article (PubMed ID: 35168881)
21. Outcomes for Muscle-invasive Bladder Cancer with Radical Cystectomy or Trimodal Therapy in US Veterans.
Kumar A; Cherry DR; Courtney PT; Nalawade V; Kotha N; Riviere PJ; Efstathiou J; McKay RR; Karim Kader A; Rose BS; Stewart TF
Eur Urol Open Sci; 2021 Aug; 30():1-10. PubMed ID: 34337540
[TBL] [Abstract][Full Text] [Related]
22. Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: A systematic review of clinical trials.
Arcangeli G; Strigari L; Arcangeli S
Crit Rev Oncol Hematol; 2015 Sep; 95(3):387-96. PubMed ID: 25934521
[TBL] [Abstract][Full Text] [Related]
23. Muscle-invasive bladder cancer organ-preserving therapy: systematic review and meta-analysis.
García-Perdomo HA; Montes-Cardona CE; Guacheta M; Castillo DF; Reis LO
World J Urol; 2018 Dec; 36(12):1997-2008. PubMed ID: 29943218
[TBL] [Abstract][Full Text] [Related]
24. Predictors of trimodality therapy in patients with muscle-invasive bladder cancer and effect on survival.
Tang Y; Lin L; Xiao Y; Meng L; Yang Y; Li X
Clin Transl Oncol; 2024 Feb; 26(2):446-455. PubMed ID: 37389736
[TBL] [Abstract][Full Text] [Related]
25. Perioperative Outcomes, Health Care Costs, and Survival After Robotic-assisted Versus Open Radical Cystectomy: A National Comparative Effectiveness Study.
Hu JC; Chughtai B; O'Malley P; Halpern JA; Mao J; Scherr DS; Hershman DL; Wright JD; Sedrakyan A
Eur Urol; 2016 Jul; 70(1):195-202. PubMed ID: 27133087
[TBL] [Abstract][Full Text] [Related]
26. Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies.
Ditonno F; Veccia A; Montanaro F; Pettenuzzo G; Franco A; Manfredi C; Triggiani L; De Nunzio C; De Sio M; Cerruto M; Crivellaro S; Kutikov A; Autorino R; Antonelli A
BJU Int; 2024 Apr; ():. PubMed ID: 38622957
[TBL] [Abstract][Full Text] [Related]
27. Trimodal therapy for invasive bladder cancer: is it really equal to radical cystectomy?
Mathieu R; Lucca I; Klatte T; Babjuk M; Shariat SF
Curr Opin Urol; 2015 Sep; 25(5):476-82. PubMed ID: 26125510
[TBL] [Abstract][Full Text] [Related]
28. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review.
Ploussard G; Daneshmand S; Efstathiou JA; Herr HW; James ND; Rödel CM; Shariat SF; Shipley WU; Sternberg CN; Thalmann GN; Kassouf W
Eur Urol; 2014 Jul; 66(1):120-37. PubMed ID: 24613684
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness of Adjuvant Chemotherapy After Radical Cystectomy for Locally Advanced and/or Pelvic Lymph Node-Positive Muscle-invasive Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Competing Risks Analysis.
Vetterlein MW; Seisen T; May M; Nuhn P; Gierth M; Mayr R; Fritsche HM; Burger M; Novotny V; Froehner M; Wirth MP; Protzel C; Hakenberg OW; Roghmann F; Palisaar RJ; Noldus J; Pycha A; Bastian PJ; Trinh QD; Xylinas E; Shariat SF; Rink M; Chun FK; Dahlem R; Fisch M; Aziz A;
Eur Urol Focus; 2018 Mar; 4(2):252-259. PubMed ID: 28753775
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Survival Outcomes With Trimodal Therapy as Primary Therapy for Non-organ-confined Bladder Cancer.
Guo Y; Jie X; Zhang A; Zhang W; Wang R; Zhang J; Mao S; Wu Y; Wang L; Zhang Z; Yan Y; Wang P; Yao X
Front Oncol; 2019; 9():1315. PubMed ID: 31867271
[No Abstract] [Full Text] [Related]
31. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
32. Use of radical cystectomy as initial therapy for the treatment of high-grade T1 urothelial carcinoma of the bladder: a SEER database analysis.
Canter D; Egleston B; Wong YN; Smaldone MC; Simhan J; Greenberg RE; Uzzo RG; Kutikov A
Urol Oncol; 2013 Aug; 31(6):866-70. PubMed ID: 21906968
[TBL] [Abstract][Full Text] [Related]
33. Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities.
Cano Garcia C; Piccinelli ML; Tappero S; Panunzio A; Barletta F; Incesu RB; Tian Z; Saad F; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Antonelli A; De Cobelli O; Kosiba M; Banek S; Kluth LA; Chun FKH; Karakiewicz PI
Int Urol Nephrol; 2023 May; 55(5):1117-1123. PubMed ID: 36813873
[TBL] [Abstract][Full Text] [Related]
34. Contemporary use trends and survival outcomes in patients undergoing radical cystectomy or bladder-preservation therapy for muscle-invasive bladder cancer.
Cahn DB; Handorf EA; Ghiraldi EM; Ristau BT; Geynisman DM; Churilla TM; Horwitz EM; Sobczak ML; Chen DYT; Viterbo R; Greenberg RE; Kutikov A; Uzzo RG; Smaldone MC
Cancer; 2017 Nov; 123(22):4337-4345. PubMed ID: 28743162
[TBL] [Abstract][Full Text] [Related]
35. The Feasibility and Safety of Reproductive Organ Preserving Radical Cystectomy for Elderly Female Patients With Muscle-Invasive Bladder Cancer: A Retrospective Propensity Score-matched Study.
Bai S; Yao Z; Zhu X; Li Z; Jiang Y; Wang R; Wen N
Urology; 2019 Mar; 125():138-145. PubMed ID: 30445122
[TBL] [Abstract][Full Text] [Related]
36. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis.
Yang M; Georgieva MV; Bocharova I; Vembusubramanian M; Qian K; Guo A; Kamat AM
Adv Ther; 2021 Mar; 38(3):1584-1600. PubMed ID: 33543424
[TBL] [Abstract][Full Text] [Related]
37. Trimodal therapy in muscle invasive bladder cancer management.
Polo-Alonso E; Kuk C; Guruli G; Paul AK; Thalmann G; Kamat A; Solsona E; Thalmann G; Urdaneta AI; Zlotta AR; Mir MC
Minerva Urol Nefrol; 2020 Dec; 72(6):650-662. PubMed ID: 33263367
[TBL] [Abstract][Full Text] [Related]
38. The effect of the time interval between diagnosis of muscle-invasive bladder cancer and radical cystectomy on staging and survival: A Netherlands Cancer Registry analysis.
Bruins HM; Aben KK; Arends TJ; van der Heijden AG; Witjes AJ
Urol Oncol; 2016 Apr; 34(4):166.e1-6. PubMed ID: 26705102
[TBL] [Abstract][Full Text] [Related]
39. Treatment of muscle-invasive bladder cancer in patients without comorbidities and fit for surgery: Trimodality therapy vs radical cystectomy. Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO).
Francolini G; Borghesi S; Fersino S; Magli A; Jereczek-Fossa BA; Cristinelli L; Rizzo M; Corvò R; Pappagallo GL; Arcangeli S; Magrini SM; D'Angelillo RM
Crit Rev Oncol Hematol; 2021 Mar; 159():103235. PubMed ID: 33493633
[TBL] [Abstract][Full Text] [Related]
40. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience.
Giacalone NJ; Shipley WU; Clayman RH; Niemierko A; Drumm M; Heney NM; Michaelson MD; Lee RJ; Saylor PJ; Wszolek MF; Feldman AS; Dahl DM; Zietman AL; Efstathiou JA
Eur Urol; 2017 Jun; 71(6):952-960. PubMed ID: 28081860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
